Published in J Hypertens on March 01, 2014
Resistant hypertension revisited: definition and true prevalence. J Hypertens (2014) 1.06
Comparative risk of renal, cardiovascular, and mortality outcomes in controlled, uncontrolled resistant, and nonresistant hypertension. Kidney Int (2015) 1.03
Cardiovascular and mortality risk of apparent resistant hypertension in women with suspected myocardial ischemia: a report from the NHLBI-sponsored WISE Study. J Am Heart Assoc (2014) 0.89
Health-related quality of life in persons with apparent treatment-resistant hypertension on at least four antihypertensives. J Hum Hypertens (2015) 0.80
Recognition and Management of Resistant Hypertension. Clin J Am Soc Nephrol (2016) 0.80
Large-scale gene-centric analysis identifies polymorphisms for resistant hypertension. J Am Heart Assoc (2014) 0.79
Lifestyle modification for resistant hypertension: The TRIUMPH randomized clinical trial. Am Heart J (2015) 0.78
Physician-pharmacist collaboration versus usual care for treatment-resistant hypertension. J Am Soc Hypertens (2016) 0.77
Reply to 'Resistant hypertension revisited: definition and true prevalence'. J Hypertens (2014) 0.76
Genetics of resistant hypertension: a novel pharmacogenomics phenotype. Curr Hypertens Rep (2015) 0.76
PTPRD gene associated with blood pressure response to atenolol and resistant hypertension. J Hypertens (2015) 0.76
Mortality Risk Associated With Resistant Hypertension Among Women: Analysis from Three Prospective Cohorts Encompassing the Spectrum of Women's Heart Disease. J Womens Health (Larchmt) (2016) 0.75
Resistant Hypertension and Renal Nerve Denervation. Methodist Debakey Cardiovasc J (2016) 0.75
Recent advances in the management of resistant hypertension. F1000Prime Rep (2015) 0.75
Clinical characteristics, target organ damage and associate risk factors of resistant hypertension determined by ambulatory blood pressure monitoring in patients aged ≥ 80 years. J Geriatr Cardiol (2017) 0.75
Increased afterload following myocardial infarction promotes conduction-dependent arrhythmias that are unmasked by hypokalemia. JACC Basic Transl Sci (2017) 0.75
Refractory versus resistant hypertension: Novel distinctive phenotypes. J Nat Sci (2017) 0.75
Resistant Hypertension, Time-Updated Blood Pressure Values and Renal Outcome in Type 2 Diabetes Mellitus. J Am Heart Assoc (2017) 0.75
The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA (2003) 97.28
Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 56.72
2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J (2013) 12.73
Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation (2006) 10.05
Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension (2008) 6.96
Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich) (2002) 6.03
Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Ann Intern Med (2006) 5.18
Prevalence of resistant hypertension in the United States, 2003-2008. Hypertension (2011) 4.61
Cardiovascular outcome in treated hypertensive patients with responder, masked, false resistant, and true resistant hypertension. Am J Hypertens (2005) 4.19
Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008. Circulation (2011) 3.95
Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation (2012) 2.99
Rationale and design of the International Verapamil SR/Trandolapril Study (INVEST): an Internet-based randomized trial in coronary artery disease patients with hypertension. J Am Coll Cardiol (1998) 2.62
Resistant hypertension: a frequent and ominous finding among hypertensive patients with atherothrombosis. Eur Heart J (2012) 1.95
The 2009 Carl Ludwig Lecture: Pathophysiology of the human sympathetic nervous system in cardiovascular diseases: the transition from mechanisms to medical management. J Appl Physiol (1985) (2009) 1.67
Daily nighttime melatonin reduces blood pressure in male patients with essential hypertension. Hypertension (2004) 1.64
Effect of different antihypertensive drug classes on central aortic pressure. Am J Hypertens (2004) 1.62
Effects of antihypertensive drugs on arterial stiffness. Cardiol Rev (2012) 1.52
Baseline predictors of resistant hypertension in the Anglo-Scandinavian Cardiac Outcome Trial (ASCOT): a risk score to identify those at high-risk. J Hypertens (2011) 1.47
Cardiovascular outcomes in hypertensive patients: comparing single-agent therapy with combination therapy. J Hypertens (2012) 1.32
Effects of renal sympathetic denervation on arterial stiffness and central hemodynamics in patients with resistant hypertension. J Am Coll Cardiol (2012) 1.04
Blood pressure modulation and cardiovascular protection by melatonin: potential mechanisms behind. Physiol Res (2007) 1.03
Prevalence and clinical characteristics of patients with true resistant hypertension in central and Eastern Europe: data from the BP-CARE study. J Hypertens (2013) 0.94
Evaluating interventions to reduce central aortic pressure, arterial stiffness and morbidity--mortality. J Hypertens (2012) 0.90
Comparison of benazepril plus amlodipine or hydrochlorothiazide in high-risk patients with hypertension and coronary artery disease. Am J Cardiol (2013) 0.87
Epidemiology, prognosis, and treatment of resistant hypertension. Pharmacotherapy (2013) 0.87
Are melatonin and its receptor agonist specific antihypertensive modulators of resistant hypertension caused by disrupted circadian rhythm? J Am Soc Hypertens (2011) 0.82
The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA (2003) 97.28
Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension (2003) 63.78
A controlled trial of renal denervation for resistant hypertension. N Engl J Med (2014) 14.22
Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med (2008) 11.61
Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med (2006) 9.40
Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med (2013) 8.74
Intensive blood-pressure control in hypertensive chronic kidney disease. N Engl J Med (2010) 8.48
Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA (2002) 8.28
Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N Engl J Med (2013) 7.54
Relation of beta-blocker-induced heart rate lowering and cardioprotection in hypertension. J Am Coll Cardiol (2008) 7.04
Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomised controlled trial. Lancet (2012) 6.69
Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med (2014) 5.93
Obesity paradox in patients with hypertension and coronary artery disease. Am J Med (2007) 5.61
Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Ann Intern Med (2006) 5.18
Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA (2010) 5.06
Perioperative beta blockers in patients having non-cardiac surgery: a meta-analysis. Lancet (2008) 5.05
β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA (2012) 4.92
Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation (2006) 4.61
Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care (2007) 4.30
Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med (2007) 4.20
Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. Arch Intern Med (2003) 4.08
Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trials. BMJ (2013) 3.98
Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of hodgkin lymphoma treated with radiation therapy. JAMA (2003) 3.93
Effect of ACAT inhibition on the progression of coronary atherosclerosis. N Engl J Med (2006) 3.90
Thiazide diuretics, potassium, and the development of diabetes: a quantitative review. Hypertension (2006) 3.89
Blood pressure targets in subjects with type 2 diabetes mellitus/impaired fasting glucose: observations from traditional and bayesian random-effects meta-analyses of randomized trials. Circulation (2011) 3.81
Intramyocardial, autologous CD34+ cell therapy for refractory angina. Circ Res (2011) 3.72
Long-term effects of renin-angiotensin system-blocking therapy and a low blood pressure goal on progression of hypertensive chronic kidney disease in African Americans. Arch Intern Med (2008) 3.71
Digoxin reduces 30-day all-cause hospital admission in older patients with chronic systolic heart failure. Am J Med (2013) 3.46
Insights from the NHLBI-Sponsored Women's Ischemia Syndrome Evaluation (WISE) Study: Part II: gender differences in presentation, diagnosis, and outcome with regard to gender-based pathophysiology of atherosclerosis and macrovascular and microvascular coronary disease. J Am Coll Cardiol (2006) 3.25
Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA (2004) 3.20
Relationship of physical fitness vs body mass index with coronary artery disease and cardiovascular events in women. JAMA (2004) 3.17
A meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus. Am J Cardiol (2007) 3.07
Role of aspiration and mechanical thrombectomy in patients with acute myocardial infarction undergoing primary angioplasty: an updated meta-analysis of randomized trials. J Am Coll Cardiol (2013) 2.99
Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. J Clin Hypertens (Greenwich) (2013) 2.94
Atrial fibrillation and obesity--results of a meta-analysis. Am Heart J (2007) 2.86
Carotid artery stenting vs carotid endarterectomy: meta-analysis and diversity-adjusted trial sequential analysis of randomized trials. Arch Neurol (2010) 2.83
Clinical practice guidelines for the management of hypertension in the community a statement by the American Society of Hypertension and the International Society of Hypertension. J Hypertens (2014) 2.82
Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin Chem (2011) 2.82
Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials. Lancet Oncol (2010) 2.77
Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Diabetes Care (2011) 2.75
Symptom presentation of women with acute coronary syndromes: myth vs reality. Arch Intern Med (2007) 2.70
Proteinuria and other markers of chronic kidney disease: a position statement of the national kidney foundation (NKF) and the national institute of diabetes and digestive and kidney diseases (NIDDK). Am J Kidney Dis (2003) 2.68
Persistent chest pain predicts cardiovascular events in women without obstructive coronary artery disease: results from the NIH-NHLBI-sponsored Women's Ischaemia Syndrome Evaluation (WISE) study. Eur Heart J (2006) 2.67
Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the INternational VErapamil-SR/trandolapril STudy (INVEST). Eur Heart J (2008) 2.64
Resistant hypertension: an overview of evaluation and treatment. J Am Coll Cardiol (2008) 2.63
Chronic kidney disease associated mortality in diastolic versus systolic heart failure: a propensity matched study. Am J Cardiol (2006) 2.58
Insights from the NHLBI-Sponsored Women's Ischemia Syndrome Evaluation (WISE) Study: Part I: gender differences in traditional and novel risk factors, symptom evaluation, and gender-optimized diagnostic strategies. J Am Coll Cardiol (2006) 2.57
Large-scale gene-centric meta-analysis across 39 studies identifies type 2 diabetes loci. Am J Hum Genet (2012) 2.53
Serum amyloid A as a predictor of coronary artery disease and cardiovascular outcome in women: the National Heart, Lung, and Blood Institute-Sponsored Women's Ischemia Syndrome Evaluation (WISE). Circulation (2004) 2.50
Adverse cardiovascular outcomes in women with nonobstructive coronary artery disease: a report from the Women's Ischemia Syndrome Evaluation Study and the St James Women Take Heart Project. Arch Intern Med (2009) 2.48
Cardiovascular events during differing hypertension therapies in patients with diabetes. J Am Coll Cardiol (2010) 2.43
Revisiting the culprit lesion in non-Q-wave myocardial infarction. Results from the VANQWISH trial angiographic core laboratory. J Am Coll Cardiol (2002) 2.41
Blood pressure control and improved cardiovascular outcomes in the International Verapamil SR-Trandolapril Study. Hypertension (2007) 2.37
The pathogenesis of diabetic nephropathy. Nat Clin Pract Endocrinol Metab (2008) 2.34
Angiotensin-converting enzyme inhibitor associated cough: deceptive information from the Physicians' Desk Reference. Am J Med (2010) 2.33
Mental stress-induced ischemia and all-cause mortality in patients with coronary artery disease: Results from the Psychophysiological Investigations of Myocardial Ischemia study. Circulation (2002) 2.32
J-curve revisited: An analysis of blood pressure and cardiovascular events in the Treating to New Targets (TNT) Trial. Eur Heart J (2010) 2.32
Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol (2004) 2.31
Abnormal coronary vasomotion as a prognostic indicator of cardiovascular events in women: results from the National Heart, Lung, and Blood Institute-Sponsored Women's Ischemia Syndrome Evaluation (WISE). Circulation (2004) 2.30
Awareness of kidney disease and relationship to end-stage renal disease and mortality. Am J Med (2012) 2.24
Retracted Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the National Institutes of Health--National Heart, Lung, and Blood Institute sponsored Women's Ischemia Syndrome Evaluation. J Clin Endocrinol Metab (2008) 2.21
Prevalence of CKD and comorbid illness in elderly patients in the United States: results from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis (2010) 2.18
Harmful effects of NSAIDs among patients with hypertension and coronary artery disease. Am J Med (2011) 2.17
Effect of allopurinol on blood pressure: a systematic review and meta-analysis. J Clin Hypertens (Greenwich) (2012) 2.16
Meta-analysis of Dense Genecentric Association Studies Reveals Common and Uncommon Variants Associated with Height. Am J Hum Genet (2010) 2.15
Independent components of chronic kidney disease as a cardiovascular risk state: results from the Kidney Early Evaluation Program (KEEP). Arch Intern Med (2007) 2.14
Pharmacogenomics of antihypertensive drugs: rationale and design of the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) study. Am Heart J (2009) 2.12